Pregnane X receptor (PXR) - A contributor to the diabetes epidemic?

Drug Metabolism and Drug Interactions

Volumn 29, Issue 1, 2014, Pages 3-15

  Hukkanen, Janne ^a,b   Hakkola, Jukka ^b,c   Rysä, Jaana ^b,c  

^a OULU UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF OULU   (Finland)

^c MEDICAL RESEARCH CENTER OULU   (Finland)

Author keywords

Diabetes; Glucose; Glucose transporter 2; Hepatosteatosis; Insulin; Pregnane X receptor

Indexed keywords

1,1 DICHLORO 2,2 BIS(4 CHLOROPHENYL)ETHANE; 1,1 DICHLORO 2,2 BIS(4 CHLOROPHENYL)ETHYLENE; 1,1,1 TRICHLORO 2 (2 CHLOROPHENYL) 2 (4 CHLOROPHENYL)ETHANE; 4,4' ISOPROPYLIDENEDIPHENOL; ALACHLOR; CHLORDANE; CHLORPHENOTANE; GLUCOSE; HEPTACHLOR EPOXIDE; HORMONE RECEPTOR STIMULATING AGENT; LIPID; NONACHLOR; PHTHALIC ACID 2 ETHYLHEXYL MONOESTER; POLYCHLORINATED BIPHENYL DERIVATIVE; PREGNANE X RECEPTOR; PREGNANE X RECEPTOR AGONIST; UNCLASSIFIED DRUG;

DISEASE ASSOCIATION; DISEASE PREDISPOSITION; ENERGY METABOLISM; ENVIRONMENTAL FACTOR; EPIDEMIC; GLUCONEOGENESIS; GLUCOSE METABOLISM; HUMAN; INSULIN RESISTANCE; LIPID LIVER LEVEL; LIPID METABOLISM; LIPID OXIDATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; REGULATORY MECHANISM; REVIEW;

ANTICHOLESTEREMIC AGENTS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; ENVIRONMENTAL EXPOSURE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPID METABOLISM; OCCUPATIONAL EXPOSURE; PLANT PREPARATIONS; RECEPTORS, STEROID;

EID: 84896798627     PISSN: 07925077     EISSN: None     Source Type: Journal    
DOI: 10.1515/dmdi-2013-0036     Document Type: Review

References (137)

1. Ihunnah CA, Jiang M, Xie W. Nuclear receptor PXR, transcriptional circuits and metabolic relevance. Biochim Biophys Acta 2011;1812: 956-63.
2. Song X, Xie M, Zhang H, Li Y, Sachdeva K, Yan B. The pregnane X receptor binds to response elements in a genomic contextdependent manner, and PXR activator rifampicin selectively alters the binding among target genes. Drug Metab Dispos 2004;32: 35-42.
3. Kojima K, Nagata K, Matsubara T, Yamazoe Y. Broad but distinct role of pregnane X receptor on the expression of individual cytochrome P450s in human hepatocytes. Drug Metab Pharmacokinet 2007;22: 276-86.
4. Zollner G, Marschall HU, Wagner M, Trauner M. Role of nuclear receptors in the adaptive response to bile acids and cholestasis: pathogenetic and therapeutic considerations. Mol Pharmacol 2006;3: 231-51.
5. Miki Y, Suzuki T, Tazawa C, Blumberg B, Sasano H. Steroid and xenobiotic receptor (SXR), cytochrome P450 3A4 and multidrug resistance gene 1 in human adult and fetal tissues. Mol Cell Endocrinol 2005;231: 75-85.
6. Chang TK, Waxman DJ. Synthetic drugs and natural products as modulators of constitutive androstane receptor (CAR) and pregnane X receptor (PXR). Drug Metab Rev 2006;38: 51-73.
7. Kojima H, Sata F, Takeuchi S, Sueyoshi T, Nagai T. Comparative study of human and mouse pregnane X receptor agonistic activity in 200 pesticides using in vitro reporter gene assays. Toxicology 2011;280: 77-87.
8. Hukkanen J. Induction of CYP enzymes: a view on human in vivo findings. Expert Rev Clin Pharmacol 2012;5: 569-85.
9. Johnson DR, Li CW, Chen LY, Ghosh JC, Chen JD. Regulation and binding of pregnane X receptor by nuclear receptor corepressor silencing mediator of retinoid and thyroid hormone receptors (SMRT). Mol Pharmacol 2006;69: 99-108.
10. Kodama S, Negishi M. PXR cross-talks with internal and external signals in physiological and pathophysiological responses. Drug Metab Rev 2013;5: 300-10.
11. Konno Y, Negishi M, Kodama S. The roles of nuclear receptors CAR and PXR in hepatic energy metabolism. Drug Metab Pharmacokinet 2008;23: 8-13.
12. Gao J, Xie W. Targeting xenobiotic receptors PXR and CAR for metabolic diseases. Trends Pharmacol Sci 2012;33: 552-8.
13. Federation ID. IDF Diabetes atlas, 5th ed. Brussels: International Diabetes Federation, 2011.
14. Wild SH, Byrne CD. ABC of obesity. Risk factors for diabetes and coronary heart disease. Br Med J 2006;333: 1009-11.
15. Neel BA, Sargis RM. The paradox of progress: environmental disruption of metabolism and the diabetes epidemic. Diabetes 2011;60: 1838-48.
16. Hectors TL, Vanparys C, van der Ven K, Martens GA, Jorens PG, Van Gaal LF, et al. Environmental pollutants and type 2 diabetes: a review of mechanisms that can disrupt beta cell function. Diabetologia 2011;54: 1273-90.
17. Baillie-Hamilton PF. Chemical toxins: a hypothesis to explain the global obesity epidemic. J Altern Complement Med 2002;8: 185-92.
18. Grun F, Blumberg B. Endocrine disrupters as obesogens. Mol Cell Endocrinol 2009;304: 19-29.
19. Bhalla S, Ozalp C, Fang S, Xiang L, Kemper JK. Ligand-activated pregnane X receptor interferes with HNF-4 signaling by targeting a common coactivator PGC-1alpha. Functional implications in hepatic cholesterol and glucose metabolism. J Biol Chem 2004;279: 45139-47.
20. Kodama S, Moore R, Yamamoto Y, Negishi M. Human nuclear pregnane X receptor cross-talk with CREB to repress cAMP activation of the glucose-6-phosphatase gene. Biochem J 2007;407: 373-81.
21. Kodama S, Koike C, Negishi M, Yamamoto Y. Nuclear receptors CAR and PXR cross talk with FOXO1 to regulate genes that encode drug-metabolizing and gluconeogenic enzymes. Mol Cell Biol 2004;24: 7931-40.
22. Zhou J, Zhai Y, Mu Y, Gong H, Uppal H, Toma D, et al. A novel pregnane X receptor-mediated and sterol regulatory elementbinding protein-independent lipogenic pathway. J Biol Chem 2006;281: 15013-20.
23. Ma Y, Liu D. Activation of pregnane X receptor by pregnenolone 16 alpha-carbonitrile prevents high-fat diet-induced obesity in AKR/J mice. PLoS One 2012;7:e38734.
24. Rysa J, Buler M, Savolainen MJ, Ruskoaho H, Hakkola J, Hukkanen J. Pregnane X receptor agonists impair postprandial glucose tolerance. Clin Pharmacol Ther 2013;93: 556-63.
25. Nakamura K, Moore R, Negishi M, Sueyoshi T. Nuclear pregnane X receptor cross-talk with FoxA2 to mediate drug-induced regulation of lipid metabolism in fasting mouse liver. J Biol Chem 2007;282: 9768-76.
26. Tuchweber B, Solymoss B, Khandekar JD, Kovacs K, Garg BD, Zsigmond G, et al. Effect of pregnenolone-16-carbonitrile on the hepatic ultrastructure, glycogen content and ethylmorphine N-demethylase activity in pregnant, fetal, and newborn rats. Exp Mol Pathol 1972;17: 281-95.
27. Kourounakis P, Szabo S, Selye H. Effect of pregnenolone- 16alpha-carbonitrile on the rat liver. Arzneimittelforschung 1976;26: 74-5.
28. He J, Gao J, Xu M, Ren S, Stefanovic-Racic M, O'Doherty RM, et al. PXR ablation alleviates diet-induced and genetic obesity and insulin resistance in mice. Diabetes 2013;62: 1876-87.
29. Takasu N, Yamada T, Miura H, Sakamoto S, Korenaga M, Nakajima K, et al. Rifampicin-induced early phase hyperglycemia in humans. Am Rev Respir Dis 1982;125: 23-7.
30. Purohit SD, Gupta PR, Agarwal KC, Sharma TN, Durlabhji P, Sharma RK. Glucose tolerance during rifampicin therapy. Ind J Tuberc 1984;31: 3-5.
31. Sharma TN, Agarwal KC, Gupta PR, Purohit SD, Sharma VK, Mathur BB. Further experience on glucose tolerance test during rifampicin therapy. J Assoc Phys India 1986;34: 131-3.
32. Gao J, He J, Zhai Y, Wada T, Xie W. The constitutive androstane receptor is an anti-obesity nuclear receptor that improves insulin sensitivity. J Biol Chem 2009;284: 25984-92.
33. Dong B, Saha PK, Huang W, Chen W, Abu-Elheiga LA, Wakil SJ, et al. Activation of nuclear receptor CAR ameliorates diabetes and fatty liver disease. Proc Natl Acad Sci USA 2009;106: 18831-6.
34. Rezen T, Tamasi V, Lovgren-Sandblom A, Bjorkhem I, Meyer UA, Rozman D. Effect of CAR activation on selected metabolic pathways in normal and hyperlipidemic mouse livers. BMC Genomics 2009;10:384.
35. Buler M, Aatsinki SM, Skoumal R, Komka Z, Toth M, Kerkela R, et al. Energy-sensing factors coactivator peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1alpha) and AMP-activated protein kinase control expression of inflammatory mediators in liver: induction of interleukin 1 receptor antagonist. J Biol Chem 2012;287: 1847-60.
36. Cheng J, Krausz KW, Tanaka N, Gonzalez FJ. Chronic exposure to rifaximin causes hepatic steatosis in pregnane X receptorhumanized mice. Toxicol Sci 2012;129: 456-68.
37. Hoekstra M, Lammers B, Out R, Li Z, Van Eck M, Van Berkel TJ. Activation of the nuclear receptor PXR decreases plasma LDL-cholesterol levels and induces hepatic steatosis in LDL receptor knockout mice. Mol Pharmacol 2009;6: 182-9.
38. Zhou J, Febbraio M, Wada T, Zhai Y, Kuruba R, He J, et al. Hepatic fatty acid transporter Cd36 is a common target of LXR, PXR, and PPARgamma in promoting steatosis. Gastroenterology 2008;134: 556-67.
39. Moreau A, Teruel C, Beylot M, Albalea V, Tamasi V, Umbdenstock T, et al. A novel pregnane X receptor and S14-mediated lipogenic pathway in human hepatocyte. Hepatology 2009;49: 2068-79.
40. Shibata M, Kihara Y, Taguchi M, Tashiro M, Otsuki M. Nonalcoholic fatty liver disease is a risk factor for type 2 diabetes in middle-aged Japanese men. Diabetes Care 2007;30: 2940-4.
41. Fan JG, Li F, Cai XB, Peng YD, Ao QH, Gao Y. Effects of nonalcoholic fatty liver disease on the development of metabolic disorders. J Gastroenterol Hepatol 2007;22: 1086-91.
42. Kim CH, Park JY, Lee KU, Kim JH, Kim HK. Fatty liver is an independent risk factor for the development of type 2 diabetes in Korean adults. Diabetes Med 2008;25: 476-81.
43. Anderson GW, Zhu Q, Metkowski J, Stack MJ, Gopinath S, Mariash CN. The Thrsp null mouse (Thrsp(tm1cnm)) and diet-induced obesity. Mol Cell Endocrinol 2009;302: 99-107.
44. Matsuzaka T, Shimano H, Yahagi N, Kato T, Atsumi A, Yamamoto T, et al. Crucial role of a long-chain fatty acid elongase, Elovl6, in obesity-induced insulin resistance. Nat Med 2007;13: 1193-202.
45. Targher G, Byrne CD. Clinical review: nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications. J Clin Endocrinol Metab 2013;98: 483-95.
46. Fahmi OA, Kish M, Boldt S, Obach RS. Cytochrome P450 3A4 mRNA is a more reliable marker than CYP3A4 activity for detecting pregnane X receptor-activated induction of drug-metabolizing enzymes. Drug Metab Dispos 2010;38: 1605-11.
47. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010;375: 735-42.
48. Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. J Am Med Assoc 2011;305: 2556-64.
49. Carter AA, Gomes T, Camacho X, Juurlink DN, Shah BR, Mamdani MM. Risk of incident diabetes among patients treated with statins: population based study. Br Med J 2013;346:f2610.
50. Zaharan NL, Williams D, Bennett K. Statins and risk of treated incident diabetes in a primary care population. Br J Clin Pharmacol 2013;75: 1118-24.
51. Culver AL, Ockene IS, Balasubramanian R, Olendzki BC, Sepavich DM, Wactawski-Wende J, et al. Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch Intern Med 2012;172: 144-52.
52. El-Sankary W, Gibson GG, Ayrton A, Plant N. Use of a reporter gene assay to predict and rank the potency and efficacy of CYP3A4 inducers. Drug Metab Dispos 2001;29: 1499-504.
53. Howe K, Sanat F, Thumser AE, Coleman T, Plant N. The statin class of HMG-CoA reductase inhibitors demonstrate differential activation of the nuclear receptors PXR, CAR and FXR, as well as their downstream target genes. Xenobiotica 2011;41: 519-29.
54. Monostory K, Pascussi JM, Szabo P, Temesvari M, Kohalmy K, Acimovic J, et al. Drug interaction potential of 2-((3,4-dichlorophenethyl) (propyl)amino)-1-(pyridin-3-yl)ethanol (LK-935), the novel nonstatin-type cholesterol-lowering agent. Drug Metab Dispos 2009;37: 375-85.
55. Feidt DM, Klein K, Hofmann U, Riedmaier S, Knobeloch D, Thasler WE, et al. Profiling induction of cytochrome P450 enzyme activity by statins using a new liquid chromatography- tandem mass spectrometry cocktail assay in human hepatocytes. Drug Metab Dispos 2010;38: 1589-97.
56. Horsmans Y, Desager JP, van den Berge V, Abrassart M, Harvengt C. Effects of simvastatin and pravastatin on 6beta-hydroxycortisol excretion, a potential marker of cytochrome P-450 3A. Pharmacol Res 1993;28: 243-8.
57. Karayalcin U, Takeda Y, Miyamori I, Morise T, Takeda R. Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor pravastatin on urinary 6beta-hydroxycortisol excretion: a preliminary study. Steroids 1991;56: 598-600.
58. Simonson SG, Martin PD, Warwick MJ, Mitchell PD, Schneck DW. The effect of rosuvastatin on oestrogen & progestin pharmacokinetics in healthy women taking an oral contraceptive. Br J Clin Pharmacol 2004;57: 279-86.
59. Willrich MA, Rodrigues AC, Cerda A, Genvigir FD, Arazi SS, Dorea EL, et al. Effects of atorvastatin on CYP3A4 and CYP3A5 mRNA expression in mononuclear cells and CYP3A activity in hypercholeresterolemic patients. Clin Chim Acta 2013;421: 157-63.
60. Watanabe H, Kosuge K, Nishio S, Yamada H, Uchida S, Satoh H, et al. Pharmacokinetic and pharmacodynamic interactions between simvastatin and diltiazem in patients with hypercholesterolemia and hypertension. Life Sci 2004;76: 281-92.
61. Luna B, Feinglos MN. Drug-induced hyperglycemia. J Am Med Assoc 2001;286: 1945-8.
62. Kalra S, Agrawal N. Diabetes and HIV: current understanding and future perspectives. Curr Diabetes Rep 2013;13: 419-27.
63. Butt AA, McGinnis K, Rodriguez-Barradas MC, Crystal S, Simberkoff M, Goetz MB, et al. HIV infection and the risk of diabetes mellitus. AIDS 2009;23: 1227-34.
64. Bigoloni A, Gianotti N, Spagnuolo V, Galli L, Nozza S, Cossarini F, et al. Long-term glucose tolerance in highly experienced HIV-infected patients receiving nucleoside analogue-sparing regimens. AIDS 2012;26: 1837-40.
65. Dussault I, Lin M, Hollister K, Wang EH, Synold TW, Forman BM. Peptide mimetic HIV protease inhibitors are ligands for the orphan receptor SXR. J Biol Chem 2001;276: 33309-12.
66. Gupta A, Mugundu GM, Desai PB, Thummel KE, Unadkat JD. Intestinal human colon adenocarcinoma cell line LS180 is an excellent model to study pregnane X receptor, but not constitutive androstane receptor, mediated CYP3A4 and multidrug resistance transporter 1 induction: studies with anti-human immunodeficiency virus protease inhibitors. Drug Metab Dispos 2008;36: 1172-80.
67. Svard J, Spiers JP, Mulcahy F, Hennessy M. Nuclear receptormediated induction of CYP450 by antiretrovirals: functional consequences of NR1I2 (PXR) polymorphisms and differential prevalence in whites and sub-Saharan Africans. J Acquir Immune Defic Syndr 2010;55: 536-49.
68. Sharma D, Lau AJ, Sherman MA, Chang TK. Agonism of human pregnane X receptor by rilpivirine and etravirine: Comparison with first generation non-nucleoside reverse transcriptase inhibitors. Biochem Pharmacol 2013;85: 1700-11.
69. Weiss J, Haefeli WE. Potential of the novel antiretroviral drug rilpivirine to modulate the expression and function of drug transporters and drug-metabolising enzymes in vitro. Int J Antimicrob Agents 2013;41: 484-7.
70. Faucette SR, Zhang TC, Moore R, Sueyoshi T, Omiecinski CJ, LeCluyse EL, et al. Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers. J Pharmacol Exp Ther 2007;320: 72-80.
71. Sahi J, Shord SS, Lindley C, Ferguson S, LeCluyse EL. Regulation of cytochrome P450 2C9 expression in primary cultures of human hepatocytes. J Biochem Mol Toxicol 2009;23: 43-58.
72. Sotaniemi EA, Arranto AJ, Sutinen S, Stengard JH. Treatment of noninsulin-dependent diabetes mellitus with enzyme inducers. Clin Pharmacol Ther 1983;33: 826-35.
73. Lahtela JT, Arranto AJ, Sotaniemi EA. Enzyme inducers improve insulin sensitivity in non-insulin-dependent diabetic subjects. Diabetes 1985;34: 911-6.
74. Lahtela JT, Sarkka P, Sotaniemi EA. Phenobarbital treatment enhances insulin mediated glucose metabolism in man. Res Commun Chem Pathol Pharmacol 1984;44: 215-26.
75. Lahtela JT, Gachalyi B, Eksyma S, Hamalainen A, Sotaniemi EA. The effect of liver microsomal enzyme inducing and inhibiting drugs on insulin mediated glucose metabolism in man. Br J Clin Pharmacol 1986;21: 19-26.
76. Korhonen T, Uusitupa M, Voutilainen E, Sarlund H, Laakso M, Laitinen M, et al. Lack of effect of hepatic enzyme induction on metabolic control in patients with type 2 (non-insulindependent) diabetes. Clin Pharmacol Ther 1987;41: 633-8.
77. Haspel HC, Stephenson KN, Davies-Hill T, El-Barbary A, Lobo JF, Croxen RL, et al. Effects of barbiturates on facilitative glucose transporters are pharmacologically specific and isoform selective. J Membr Biol 1999;169: 45-53.
78. Honkanen RA, McBath H, Kushmerick C, Callender GE, Scarlata SF, Fenstermacher JD, et al. Barbiturates inhibit hexose transport in cultured mammalian cells and human erythrocytes and interact directly with purified GLUT-1. Biochemistry 1995;34: 535-44.
79. Chaudhry AS, Urban TJ, Lamba JK, Birnbaum AK, Remmel RP, Subramanian M, et al. CYP2C9*1B promoter polymorphisms, in linkage with CYP2C19*2, affect phenytoin autoinduction of clearance and maintenance dose. J Pharmacol Exp Ther 2010;332: 599-611.
80. Phabphal K, Limapichat K, Sathirapanya P, Setthawatcharawanich S, Geater A. Characterization of glucose homeostasis and lipid profile in adult, seizure-free, epileptic patients in Asian population. Eur J Neurol 2012;19: 1228-34.
81. Draznin B, Ayalon D, Hoerer E, Oberman Z, Harell A, Ravid R, et al. Effect of diphenylhydantoin on patterns of insulin secretion in obese subjects. Acta Diabetol Lat 1977;14: 51-61.
82. Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH. Effect of diphenylhydantoin on insulin secretion in man. N Engl J Med 1972;286: 339-42.
83. Levin SR, Reed JW, Ching KN, Davis JW, Blum MR, Forsham PH. Diphenylhydantoin. Its use in detecting early insulin secretory defects in patients with mild glucose intolerance. Diabetes 1973;22: 194-201.
84. Perry-Keene DA, Larkins RG, Heyma P, Peter CT, Ross D, Sloman JG. The effect of long-term diphenylhydantoin therapy on glucose tolerance and insulin secretion: a controlled trial. Clin Endocrinol (Oxf) 1980;12: 575-80.
85. Siegel EG, Janjic D, Wollheim CB. Phenytoin inhibition of insulin release. Studies on the involvement of Ca2+ fluxes in rat pancreatic islets. Diabetes 1982;31: 265-9.
86. Li L, Stanton JD, Tolson AH, Luo Y, Wang H. Bioactive terpenoids and flavonoids from Ginkgo biloba extract induce the expression of hepatic drug-metabolizing enzymes through pregnane X receptor, constitutive androstane receptor, and aryl hydrocarbon receptor-mediated pathways. Pharmacol Res 2009;26: 872-82.
87. Kudolo GB. The effect of 3-month ingestion of Ginkgo biloba extract on pancreatic beta-cell function in response to glucose loading in normal glucose tolerant individuals. J Clin Pharmacol 2000;40: 647-54.
88. Kudolo GB. The effect of 3-month ingestion of Ginkgo biloba extract (EGb 761) on pancreatic beta-cell function in response to glucose loading in individuals with non-insulin-dependent diabetes mellitus. J Clin Pharmacol 2001;41: 600-11.
89. Kudolo GB, Dorsey S, Blodgett J. Effect of the ingestion of Ginkgo biloba extract on platelet aggregation and urinary prostanoid excretion in healthy and type 2 diabetic subjects. Thromb Res 2002;108: 151-60.
90. Kudolo GB, Wang W, Elrod R, Barrientos J, Haase A, Blodgett J. Short-term ingestion of Ginkgo biloba extract does not alter whole body insulin sensitivity in non-diabetic, pre-diabetic or type 2 diabetic subjects - a randomized double-blind placebocontrolled crossover study. Clin Nutr 2006;25: 123-34.
91. Moore LB, Goodwin B, Jones SA, Wisely GB, Serabjit-Singh CJ, Willson TM, et al. St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci USA 2000;97: 7500-2.
92. Krausova L, Stejskalova L, Wang H, Vrzal R, Dvorak Z, Mani S, et al. Metformin suppresses pregnane X receptor (PXR)-regulated transactivation of CYP3A4 gene. Biochem Pharmacol 2011;82: 1771-80.
93. Thayer KA, Heindel JJ, Bucher JR, Gallo MA. Role of environmental chemicals in diabetes and obesity: a National Toxicology Program workshop review. Environ Health Perspect 2012;120: 779-89.
94. Taylor KW, Novak RF, Anderson HA, Birnbaum LS, Blystone C, Devito M, et al. Evaluation of the association between persistent organic pollutants (POPs) and diabetes in epidemiological studies: a National Toxicology Program workshop review. Environ Health Perspect 2013;21: 774-83.
95. Hernandez JP, Mota LC, Baldwin WS. Activation of CAR and PXR by dietary, environmental and occupational chemicals alters drug metabolism, intermediary metabolism, and cell proliferation. Curr Pharmacogenomics Person Med 2009;7: 81-105.
96. Abass K, Lamsa V, Reponen P, Kublbeck J, Honkakoski P, Mattila S, et al. Characterization of human cytochrome P450 induction by pesticides. Toxicology 2012;294: 17-26.
97. Al-Salman F, Plant N. Non-coplanar polychlorinated biphenyls (PCBs) are direct agonists for the human pregnane-X receptor and constitutive androstane receptor, and activate target gene expression in a tissue-specific manner. Toxicol Appl Pharmacol 2012;263: 7-13.
98. Kretschmer XC, Baldwin WS. CAR and PXR: xenosensors of endocrine disrupters? Chem Biol Interact 2005;155: 111-28.
99. Lemaire G, Mnif W, Pascussi JM, Pillon A, Rabenoelina F, Fenet H, et al. Identification of new human pregnane X receptor ligands among pesticides using a stable reporter cell system. Toxicol Sci 2006;91: 501-9.
100. Montgomery MP, Kamel F, Saldana TM, Alavanja MC, Sandler DP. Incident diabetes and pesticide exposure among licensed pesticide applicators: Agricultural Health Study, 1993-2003. Am J Epidemiol 2008;167: 1235-46.
101. Patel CJ, Bhattacharya J, Butte AJ. An Environment-Wide Association Study (EWAS) on type 2 diabetes mellitus. PLoS One 2010;5:e10746.
102. Son HK, Kim SA, Kang JH, Chang YS, Park SK, Lee SK, et al. Strong associations between low-dose organochlorine pesticides and type 2 diabetes in Korea. Environ Int 2010;36: 410-4.
103. Lee DH, Lee IK, Song K, Steffes M, Toscano W, Baker BA, et al. A strong dose-response relation between serum concentrations of persistent organic pollutants and diabetes: results from the National Health and Examination Survey 1999-2002. Diabetes Care 2006;29: 1638-44.
104. Lee DH, Lind PM, Jacobs DR Jr, Salihovic S, van Bavel B, Lind L. Polychlorinated biphenyls and organochlorine pesticides in plasma predict development of type 2 diabetes in the elderly: the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) study. Diabetes Care 2011;34: 1778-84.
105. Codru N, Schymura MJ, Negoita S, Rej R, Carpenter DO. Diabetes in relation to serum levels of polychlorinated biphenyls and chlorinated pesticides in adult Native Americans. Environ Health Perspect 2007;115: 1442-7.
106. Cox S, Niskar AS, Narayan KM, Marcus M. Prevalence of self-reported diabetes and exposure to organochlorine pesticides among Mexican Americans: Hispanic Health and nutrition examination survey, 1982-1984. Environ Health Perspect 2007;115: 1747-52.
107. Philibert A, Schwartz H, Mergler D. An exploratory study of diabetes in a First Nation community with respect to serum concentrations of p,p'-DDE and PCBs and fish consumption. Int J Environ Res Public Health 2009;6: 3179-89.
108. Rignell-Hydbom A, Rylander L, Hagmar L. Exposure to persistent organochlorine pollutants and type 2 diabetes mellitus. Hum Exp Toxicol 2007;26: 447-52.
109. Rignell-Hydbom A, Lidfeldt J, Kiviranta H, Rantakokko P, Samsioe G, Agardh CD, et al. Exposure to p,p'-DDE: a risk factor for type 2 diabetes. PLoS One 2009;4:e7503.
110. Rylander L, Rignell-Hydbom A, Hagmar L. A cross-sectional study of the association between persistent organochlorine pollutants and diabetes. Environ Health 2005;4:28.
111. Turyk M, Anderson H, Knobeloch L, Imm P, Persky V. Organochlorine exposure and incidence of diabetes in a cohort of Great Lakes sport fish consumers. Environ Health Perspect 2009;117: 1076-82.
112. Airaksinen R, Rantakokko P, Eriksson JG, Blomstedt P, Kajantie E, Kiviranta H. Association between type 2 diabetes and exposure to persistent organic pollutants. Diabetes Care 2011;34: 1972-9.
113. Everett CJ, Frithsen IL, Diaz VA, Koopman RJ, Simpson WM Jr, Mainous AG 3rd. Association of a polychlorinated dibenzop- dioxin, a polychlorinated biphenyl, and DDT with diabetes in the 1999-2002 National Health and Nutrition Examination Survey. Environ Res 2007;103: 413-8.
114. Lee DH, Lee IK, Steffes M, Jacobs DR Jr. Extended analyses of the association between serum concentrations of persistent organic pollutants and diabetes. Diabetes Care 2007;30: 1596-8.
115. Jacobs MN, Nolan GT, Hood SR. Lignans, bacteriocides and organochlorine compounds activate the human pregnane X receptor (PXR). Toxicol Appl Pharmacol 2005;209: 123-33.
116. Lee DH, Steffes MW, Sjodin A, Jones RS, Needham LL, Jacobs DR Jr. Low dose of some persistent organic pollutants predicts type 2 diabetes: a nested case-control study. Environ Health Perspect 2010;118: 1235-42.
117. Hurst CH, Waxman DJ. Environmental phthalate monoesters activate pregnane X receptor-mediated transcription. Toxicol Appl Pharmacol 2004;199: 266-74.
118. James-Todd T, Stahlhut R, Meeker JD, Powell SG, Hauser R, Huang T, et al. Urinary phthalate metabolite concentrations and diabetes among women in the National Health and Nutrition Examination Survey (NHANES) 2001-2008. Environ Health Perspect 2012;120: 1307-13.
119. Takeshita A, Koibuchi N, Oka J, Taguchi M, Shishiba Y, Ozawa Y. Bisphenol-A, an environmental estrogen, activates the human orphan nuclear receptor, steroid and xenobiotic receptormediated transcription. Eur J Endocrinol 2001;145: 513-7.
120. Lang IA, Galloway TS, Scarlett A, Henley WE, Depledge M, Wallace RB, et al. Association of urinary bisphenol A concentration with medical disorders and laboratory abnormalities in adults. J Am Med Assoc 2008;300: 1303-10.
121. Sui Y, Ai N, Park SH, Rios-Pilier J, Perkins JT, Welsh WJ, et al. Bisphenol A and its analogues activate human pregnane X receptor. Environ Health Perspect 2012;120: 399-405.
122. Melzer D, Rice NE, Lewis C, Henley WE, Galloway TS. Association of urinary bisphenol a concentration with heart disease: evidence from NHANES 2003/06. PLoS One 2010;5:e8673.
123. Fierens S, Mairesse H, Heilier JF, De Burbure C, Focant JF, Eppe G, et al. Dioxin/polychlorinated biphenyl body burden, diabetes and endometriosis: findings in a population-based study in Belgium. Biomarkers 2003;8: 529-34.
124. Vasiliu O, Cameron L, Gardiner J, Deguire P, Karmaus W. Polybrominated biphenyls, polychlorinated biphenyls, body weight, and incidence of adult-onset diabetes mellitus. Epidemiology 2006;17: 352-9.
125. Uemura H, Arisawa K, Hiyoshi M, Satoh H, Sumiyoshi Y, Morinaga K, et al. Associations of environmental exposure to dioxins with prevalent diabetes among general inhabitants in Japan. Environ Res 2008;108: 63-8.
126. Wang SL, Tsai PC, Yang CY, Guo YL. Increased risk of diabetes and polychlorinated biphenyls and dioxins: a 24-year follow-up study of the Yucheng cohort. Diabetes Care 2008;31: 1574-9.
127. Turyk M, Anderson HA, Knobeloch L, Imm P, Persky VW. Prevalence of diabetes and body burdens of polychlorinated biphenyls, polybrominated diphenyl ethers, and p,p'- diphenyldichloroethene in Great Lakes sport fish consumers. Chemosphere 2009;75: 674-9.
128. Ukropec J, Radikova Z, Huckova M, Koska J, Kocan A, Sebokova E, et al. High prevalence of prediabetes and diabetes in a population exposed to high levels of an organochlorine cocktail. Diabetologia 2010;53: 899-906.
129. Grandjean P, Henriksen JE, Choi AL, Petersen MS, Dalgard C, Nielsen F, et al. Marine food pollutants as a risk factor for hypoinsulinemia and type 2 diabetes. Epidemiology 2011;22: 410-7.
130. Persky V, Piorkowski J, Turyk M, Freels S, Chatterton R Jr, Dimos J, et al. Associations of polychlorinated biphenyl exposure and endogenous hormones with diabetes in post-menopausal women previously employed at a capacitor manufacturing plant. Environ Res 2011;111: 817-24.
131. Persky V, Piorkowski J, Turyk M, Freels S, Chatterton R Jr, Dimos J, et al. Polychlorinated biphenyl exposure, diabetes and endogenous hormones: a cross-sectional study in men previously employed at a capacitor manufacturing plant. Environ Health 2012;11:57.
132. Silverstone AE, Rosenbaum PF, Weinstock RS, Bartell SM, Foushee HR, Shelton C, et al. Polychlorinated biphenyl (PCB) exposure and diabetes: results from the Anniston Community Health Survey. Environ Health Perspect 2012;120: 727-32.
133. Everett CJ, Thompson OM. Associations of dioxins, furans and dioxin-like PCBs with diabetes and pre-diabetes: is the toxic equivalency approach useful? Environ Res 2012;118: 107-11.
134. Tanaka T, Morita A, Kato M, Hirai T, Mizoue T, Terauchi Y, et al. Congener-specific polychlorinated biphenyls and the prevalence of diabetes in the Saku Control Obesity Program (SCOP). Endocr J 2011;58: 589-96.
135. Poland A, Smith D, Kuntzman R, Jacobson M, Conney AH. Effect of intensive occupational exposure to DDT on phenylbutazone and cortisol metabolism in human subjects. Clin Pharmacol Ther 1970;11: 724-32.
136. Lee DH, Steffes MW, Sjodin A, Jones RS, Needham LL, Jacobs DR Jr. Low dose organochlorine pesticides and polychlorinated biphenyls predict obesity, dyslipidemia, and insulin resistance among people free of diabetes. PLoS One 2011;6:e15977.
137. Kolodkin A, Sahin N, Phillips A, Hood SR, Bruggeman FJ, Westerhoff HV, et al. Optimization of stress response through the nuclear receptor-mediated cortisol signalling network. Nat Commun 2013;4:1792.